Skandinaviska Enskilda Banken Ab (Publ) Viking Therapeutics, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $21.5 Billion
- Q3 2024
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 28,418 shares of VKTX stock, worth $927,847. This represents 0.01% of its overall portfolio holdings.
Number of Shares
28,418
Previous 28,418
-0.0%
Holding current value
$927,847
Previous $1.51 Million
19.46%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding VKTX
# of Institutions
476Shares Held
63.4MCall Options Held
5.76MPut Options Held
3.39M-
Vanguard Group Inc Valley Forge, PA10.2MShares$332 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$197 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$153 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$69.1 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.87MShares$61.2 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.5B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...